Table 2.
Clinical characteristics of patients with IgAN who did/did not achieve clinical remission
| Parameters | Clinical Remission (n=51) | No Clinical Remission (n=26) | P Value |
|---|---|---|---|
| Age (yr), mean±SD | 36.2±10.3 | 39.4±11.1 | 0.21 |
| Male, n (%) | 35 (68.6) | 13 (50.0) | 0.11 |
| BMI (kg/m2), mean±SD | 24.2±3.5 | 26.1±5.1 | 0.06 |
| WBC (109/L), mean±SD | 6.6±1.8 | 7.5±2.4 | 0.11 |
| Platelets (109/L), mean±SD | 224.1±63.0 | 236.5±71.6 | 0.44 |
| Anemia, n (%) | 6 (11.8) | 7 (26.9) | 0.09 |
| Albumin (g/L), mean±SD | 39.2±4.3 | 37.5±6.2 | 0.17 |
| SCr (μmol/L), mean±SD | 109.5±40.0 | 106.4±42.9 | 0.75 |
| eGFR (ml/min per 1.73 m2), mean±SD | 73.7±28.1 | 70.8±35.0 | 0.70 |
| eGFR <60 ml/min per 1.73 m2, n (%) | 18 (35.3) | 12 (46.2) | 0.36 |
| Hypertension, n (%) | 11 (21.6) | 10 (38.5) | 0.12 |
| Proteinuria (mg/d), median (IQR) | 1349.0 (818.0–1669.5) | 1541.5 (1083.8–3720.0) | 0.04 |
| Proteinuria >1.0 g/d, n (%) | 34 (66.7) | 20 (76.9) | 0.35 |
| Cystatin C (mg/L), median (IQR) | 1.19 (0.97–1.59) | 1.33 (1.12–1.71) | 0.13 |
| Uric acid (μmol/L), median (IQR) | 368.0 (278.5–430.5) | 380.0 (300.5–467.5) | 0.37 |
| Serum urea (mmol/L), median (IQR) | 5.6 (6.3–7.9) | 6.1 (4.7–9.3) | 0.71 |
| Histologic lesion scoring, n (%) | |||
| M1 | 34 (66.7) | 20 (76.9) | 0.35 |
| E1 | 10 (19.6) | 4 (15.4) | 0.65 |
| S1 | 42 (82.4) | 25 (96.2) | 0.09 |
| T lesion scoring | |||
| T0 | 23 (45.1) | 12 (46.2) | 0.79 |
| T1 | 19 (37.3) | 8 (30.8) | |
| T2 | 9 (17.6) | 6 (23.1) | |
| C lesion scoring | |||
| C0 | 30 (58.8) | 13 (66.1) | 0.76 |
| C1 | 18 (35.3) | 11 (29.9) | |
| C2 | 3 (5.9) | 2 (3.9) | |
WBC, white blood cell; SCr, serum creatinine; IQR, interquartile range; NA, not available; M1, mesangial hypercellularity; E1, endocapillary hypercellularity; S1, segmental glomerulosclerosis; T, tubular atrophy/interstitial fibrosis; T0, T ≤25%; T1, T 26%–50%; T2, T >50%; C0, no crescents; C1, crescents in less than one fourth of glomeruli; C2, crescents in over one fourth of glomeruli.